Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alzamend Neuro Inc (NQ: ALZN )

1.160 +0.010 (+0.87%)
Streaming Delayed Price Updated: 3:58 PM EST, Dec 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,139
Open 1.170
Bid (Size) 1.150 (1)
Ask (Size) 1.160 (2)
Prev. Close 1.150
Today's Range 1.140 - 1.190
52wk Range 0.8005 - 3.160
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
Via ACCESSWIRE

Performance

YTD
-42.29%
-42.29%
1 Month
+1.75%
+1.75%
3 Month
+23.93%
+23.93%
6 Month
+21.53%
+21.53%
1 Year
-40.51%
-40.51%

More News

Read More
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
Via Benzinga
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
Via Benzinga
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study
Via Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
From Alzamend Neuro, Inc.
Via Business Wire
WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying
Via Benzinga
Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate
Via Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
From Alzamend Neuro, Inc.
Via Business Wire
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
Via Benzinga
Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data
Via Benzinga
6 Penny Stocks With 1,000% Upside Potential
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
4 Stocks Under $1 Insiders Are Aggressively Buying
Via Benzinga
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Executives Buy Around $5M Of 4 Penny Stocks
Via Benzinga
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.